Ozempic And Wegovy May Reduce Inflammation As Well As Weight Loss

Do Ozempic and Wegovy reduce inflammation as well as support weight loss, and what does the evidence show in Europe?Ozempic and Wegovy explained: semaglutide, GLP-1 receptor agonists, weight reduction, inflammatory markers, and cardiometabolic risk.In this episode, we review research suggesting semaglutide may influence inflammatory pathways in addition to promoting weight loss, and how doctors interpret these findings under EU medical guidance.You’ll learn:• How GLP-1 receptor agonists improve glucose regulation and appetite control• Why weight loss itself can reduce systemic inflammation• The role of markers such as C-reactive protein (CRP)• Evidence linking semaglutide to cardiovascular risk reduction• The difference between direct anti-inflammatory effects and secondary metabolic benefits• Common side effects and safety monitoring requirements• Situations where treatment requests may be declined pending BMI, HbA1c, or medical reviewWe explain how doctors assess BMI, waist circumference, HbA1c, lipid profile, blood pressure, gastrointestinal tolerance, and overall cardiovascular risk during an online consultation in the EU. Anti-inflammatory benefits are not a standalone prescribing indication and must be considered within approved metabolic criteria.This episode reflects the clinical standards used by Mobi Doctor, where weight management consultations are reviewed by a registered physician in line with EU prescribing guidance.Read the full guide and transcript here:https://www.mobidoctor.eu/blog/ozempic-and-wegovy-may-reduce-inflammation-as-well-as-weight-loss